What’s new in breast pathology 2022: WHO 5th edition and biomarker updates
1
조회
0
다운로드
0
인용
0
참고문헌
초록
The 5th edition WHO Classification of Breast Tumours (2019) has introduced changes to our practices. Highlights are presented below, with a focus on modifications to morphological subtype categorization. In addition, we summarize important updates to ER and PR testing made in the 2020 ASCO/CAP guidelines, and briefly discuss PD-L1 and Ki-67 testing in breast cancer.
Abstract
The 5th edition WHO Classification of Breast Tumours (2019) has introduced changes to our practices. Highlights are presented below, with a focus on modifications to morphological subtype categorization. In addition, we summarize important updates to ER and PR testing made in the 2020 ASCO/CAP guidelines, and briefly discuss PD-L1 and Ki-67 testing in breast cancer.
참고문헌 (1)
- Allison KH, "Estrogen and progesterone receptor testing in breast cancer : American Society of Clinical Oncology", College of American Pathologists Guideline Update, 2020, pp.144, 545~563